UNSPSC 51171841: Iprozilamine

This classification denotes an antiemetic agent with the molecular formula C13H22ClN5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8WTG4RSP9Y, chemically known as pyrimidine, 4-chloro-2-isopropylamino-6-(4-methylpiperazino)-5-methylthio- but generally known as iprozilamine, which bears US NIH Compound Identifier 68725. European Medicines Agency schedules Iprozilamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08288MIG.

UNSPSC 51171841 Iprozilamine is a Commodity-tier code representing a specific pharmaceutical active ingredient, but state and local procurement activity under this code does not align with the nominal product scope. The recent opportunities posted under this code include offender drug testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical cooperative purchasing — none of which specifically procure iprozilamine or name it as a required ingredient. The mismatch suggests that either the code is being used as a catch-all classification for broader pharmaceutical and drug-testing procurements, or the tagging reflects administrative coding practices that do not correspond to the chemical substance the code nominally describes.

State and local issuing bodies posting under this code span county corrections departments, state health agencies, and multi-state cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a response deadline of July 23, 2026, seeking a contractor to operate two collection sites and perform immunoassay screening and confirmatory testing (LC/MS/MS or GC/MS) for approximately 25,031 tests annually under a two-year contract estimated at $600,000. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026 seeking generic pharmaceutical and OTC product suppliers for multi-state distribution, with proposals due March 26, 2026. Geographic activity centers on Texas and Minnesota, with MMCAP's cooperative purchasing extending to Oregon and other participating jurisdictions. The code shows limited recent activity directly aligned to iprozilamine procurement; firms should verify whether opportunities tagged under this code match their product and service capabilities before pursuing.